Gaye Öztürk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gaye Öztürk has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Betül Rabia Erdoğan
İzmir Katip Çelebi Üniversitesi
1 shared publication - Ebru Arioglu-Inan
Ankara University
1 shared publication - Irem Karaomerlioglu
ANKARA ÜNİVERSİTESİ, ECZACILIK FAKÜLTESİ, ECZACILIK MESLEK BİLİMLERİ BÖLÜMÜ, FARMAKOLOJİ ANABİLİM DALI
1 shared publication - Kerem Erdoğan
Hacettepe Üniversitesi
1 shared publication - Martin Christian Michel
Department of Pharmacology, University Medical Center, Johannes Gutenberg University, 55131 Mainz, Germany
1 shared publication - Melike Hacer Özkan
Hacettepe Univ, Fac Pharm, Dept Pharmacol, Ankara, Turkiye
1 shared publication
Latest Publications
- 30 October 2026
- Published by FABAD Farmasotik Bilimler Ankara Dernegi in Fabad Journal of Pharmaceutical Sciences
- Vol. 51 (3) , 1561-1578
The Endocannabinoid System in Allergic Airway Diseases: Mechanisms and Therapeutic Potential
Allergic airway diseases, including allergic asthma and rhinitis, are characterised by airway inflammation and altered responses to inhaled allergens. The endocannabinoid system (ECS) significantly contributes to the regulation of airway tone and immune system activity. Experimental studies indicate that cannabinoid receptor ligands and inhibitors of endocannabinoid metabolism can modify airway hyperreactivity, inflammatory cell recruitment, and allergic inflammation. However, these effects are not uniform. CB1 and CB2 receptor signalling may produce different outcomes depending on the ligand, responding cell population, tissue, and experimental model. Endocannabinoid-related lipids may likewise exert protective or pro-inflammatory effects through different pathways. Evidence for therapeutic targeting of the ECS is more extensive in allergic asthma, where improvements in airway function or inflammation have been reported. In allergic rhinitis, pharmacological evidence remains limited, and the available clinical findings are insufficient to draw definitive conclusions. The established data suggests the ECS as a potential target in allergic airway diseases while underscoring the need to clarify receptor-dependent and receptor-independent mechanisms mediating their effects and establish efficacy and safety in well-characterized human populations. This review focuses on the role of the ECS in allergic airway diseases and evaluates its potential as a therapeutic target.
- 30 October 2026
- Published by FABAD Farmasotik Bilimler Ankara Dernegi in Fabad Journal of Pharmaceutical Sciences
- Vol. 51 (3) , 1561-1578
The Endocannabinoid System in Allergic Airway Diseases: Mechanisms and Therapeutic Potential
Allergic airway diseases, including allergic asthma and rhinitis, are characterised by airway inflammation and altered responses to inhaled allergens. The endocannabinoid system (ECS) significantly contributes to the regulation of airway tone and immune system activity. Experimental studies indicate that cannabinoid receptor ligands and inhibitors of endocannabinoid metabolism can modify airway hyperreactivity, inflammatory cell recruitment, and allergic inflammation. However, these effects are not uniform. CB1 and CB2 receptor signalling may produce different outcomes depending on the ligand, responding cell population, tissue, and experimental model. Endocannabinoid-related lipids may likewise exert protective or pro-inflammatory effects through different pathways. Evidence for therapeutic targeting of the ECS is more extensive in allergic asthma, where improvements in airway function or inflammation have been reported. In allergic rhinitis, pharmacological evidence remains limited, and the available clinical findings are insufficient to draw definitive conclusions. The established data suggests the ECS as a potential target in allergic airway diseases while underscoring the need to clarify receptor-dependent and receptor-independent mechanisms mediating their effects and establish efficacy and safety in well-characterized human populations. This review focuses on the role of the ECS in allergic airway diseases and evaluates its potential as a therapeutic target.
- 11 January 2026
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 30 (1) , 60-71
Lack of evidence for improved β-adrenoceptor-mediated papillary muscle contraction by low-dose empagliflozin treatment in a rat model of streptozotocin-induced diabetes
Diabetes mellitus leads to cardiovascular complications including impaired cardiac β-adrenoceptor (β-AR) function. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, such as empagliflozin (EMPA), improve outcomes in heart failure patients and animal models. Therefore, we have investigated the effects of EMPA on in vivo cardiac function and β-AR mediated contractile responses in streptozotocin (STZ)-induced diabetes in a design reflecting late-onset of treatment. Male Sprague Dawley rats were divided into 4 groups (control, EMPA-treated control, diabetic, and EMPA- treated diabetic). Diabetes was induced by STZ injection (40 mg/kg). 13-16 weeks after STZ injection, a low dose of EMPA (10 mg/kg/day, daily oral gavage) or vehicle was administered for another 8 weeks. At the end of the treatment period, in vivo cardiac function was evaluated by pressure-volume (PV) loop analysis and β-AR mediated contractile response was determined by isoprenaline on isolated papillary strips. The blood glucose-lowering effect of low-dose EMPA was confirmed. EMPA did not change cardiac function in control rats. Diabetic rats had a reduced heart rate, cardiac output, stroke work, rate of contraction and rate of relaxation and increased isovolumic relaxation, whereas in vitro responses were not markedly attenuated. Treatment with EMPA showed a trend for improvement of some (e.g., stroke volume, ejection fraction, cardiac index) but not all parameters. Our results indicate that low-dose EMPA treatment had limited effects on cardiac impairment despite reducing blood glucose when initiated after diabetes has manifested. Future studies using a preventive rather than therapeutic approach could help to clarify the possible benefits of EMPA on the diabetic heart.
- 11 January 2026
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 30 (1) , 60-71
Lack of evidence for improved β-adrenoceptor-mediated papillary muscle contraction by low-dose empagliflozin treatment in a rat model of streptozotocin-induced diabetes
Diabetes mellitus leads to cardiovascular complications including impaired cardiac β-adrenoceptor (β-AR) function. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, such as empagliflozin (EMPA), improve outcomes in heart failure patients and animal models. Therefore, we have investigated the effects of EMPA on in vivo cardiac function and β-AR mediated contractile responses in streptozotocin (STZ)-induced diabetes in a design reflecting late-onset of treatment. Male Sprague Dawley rats were divided into 4 groups (control, EMPA-treated control, diabetic, and EMPA- treated diabetic). Diabetes was induced by STZ injection (40 mg/kg). 13-16 weeks after STZ injection, a low dose of EMPA (10 mg/kg/day, daily oral gavage) or vehicle was administered for another 8 weeks. At the end of the treatment period, in vivo cardiac function was evaluated by pressure-volume (PV) loop analysis and β-AR mediated contractile response was determined by isoprenaline on isolated papillary strips. The blood glucose-lowering effect of low-dose EMPA was confirmed. EMPA did not change cardiac function in control rats. Diabetic rats had a reduced heart rate, cardiac output, stroke work, rate of contraction and rate of relaxation and increased isovolumic relaxation, whereas in vitro responses were not markedly attenuated. Treatment with EMPA showed a trend for improvement of some (e.g., stroke volume, ejection fraction, cardiac index) but not all parameters. Our results indicate that low-dose EMPA treatment had limited effects on cardiac impairment despite reducing blood glucose when initiated after diabetes has manifested. Future studies using a preventive rather than therapeutic approach could help to clarify the possible benefits of EMPA on the diabetic heart.
- Open Access
- 2 October 2024
- Published by FABAD Farmasotik Bilimler Ankara Dernegi in Fabad Journal of Pharmaceutical Sciences
- Vol. 49 (3) , 513-524
Does Functionality of Perivascular Adipose Tissue Decrease in the Adult Rat Thoracic Aorta?
Perivasküler adipoz doku (PVAD) parakrin faktörler salıvererek kasılma-karşıtı etki ile damar tonusunu düzenler. Yaşlanma, insanlarda ve kemirgenlerde damar yapısını ve işlevini bozan bağımsız bir risk faktörü olarak kabul edilir. Yaşlanmanın PVAD işlevi üzerine etkilerini inceleyen sınırlı sayıda çalışma vardır. Biz bu çalışmada, 10-12 haftalık genç ve 52 haftalık erişkin Wistar erkek sıçanların izole torasik aortasında PVAD varlığında ve yokluğunda noradrenalin kasılmalarını ve asetilkolin ile elde edilen endotele bağlı gevşemeleri inceledik. Noradrenalin kasılmaları hem genç hem de erişkin gruba ait PVAD’ı sağlam torasik aorta halkalarında PVAD’ı sıyrılmış olanlara göre düşüktü. PVAD yokluğunda erişkin sıçan torasik aortunda elde edilen noradrenalin kasılmalarının boyu genç sıçan aortuna kıyasla anlamlı derecede yüksekti. Ancak bu arterlerde PVAD sağlam bırakıldığında, noradrenalin kasılma boyu ve duyarlılığı genç ve erişkin grupta benzerdi, bu da PVAD’ın erişkin sıçanlarda kasılma-karşıtı işlevinin devam ettiğini gösterdi. Genç sıçan torasik aortunda noradrenalin kasılmaları, nitrik oksit (NO) sentaz inhibitörü L-NAME varlığında güçlenerek arttı ve bu artış oranı PVAD varlığında daha düşüktü. Ancak, L-NAME'in erişkin grupta noradrenalin -aracılı kasılmalardaki güçlendirici etkisi PVAD varlığında değişmedi. Asetilkolin-kaynaklı ve endotel-bağımlı gevşemeler erişkin grupta genç gruba kıyasla önemli ölçüde azaldı. PVAD’ın sağlam bırakılması genç sıçan aortunda endotele bağlı gevşemeleri etkilemezken, yaşlı sıçan aortunda azalmış asetilkolin gevşemeleri daha da azaldı. Sonuç olarak, PVAD'ın kasılma-karşıtı işlevinin erişkin sıçanlarda devam ettiği ve tonik inhibitör etkiyle damardaki kasılmayı sınırladığı belirlenmiştir. Ancak, elde edilen verilere göre erişkin sıçan aortunda endotele bağlı gevşemelerin azalması ile birlikte PVAD ile endotel arasındaki çapraz sinyal etkileşiminin de bozulduğu düşünülmektedir.
- 2 October 2024
- Published by FABAD Farmasotik Bilimler Ankara Dernegi in Fabad Journal of Pharmaceutical Sciences
- Vol. 49 (3) , 513-524
Open AccessDoes Functionality of Perivascular Adipose Tissue Decrease in the Adult Rat Thoracic Aorta?
Perivasküler adipoz doku (PVAD) parakrin faktörler salıvererek kasılma-karşıtı etki ile damar tonusunu düzenler. Yaşlanma, insanlarda ve kemirgenlerde damar yapısını ve işlevini bozan bağımsız bir risk faktörü olarak kabul edilir. Yaşlanmanın PVAD işlevi üzerine etkilerini inceleyen sınırlı sayıda çalışma vardır. Biz bu çalışmada, 10-12 haftalık genç ve 52 haftalık erişkin Wistar erkek sıçanların izole torasik aortasında PVAD varlığında ve yokluğunda noradrenalin kasılmalarını ve asetilkolin ile elde edilen endotele bağlı gevşemeleri inceledik. Noradrenalin kasılmaları hem genç hem de erişkin gruba ait PVAD’ı sağlam torasik aorta halkalarında PVAD’ı sıyrılmış olanlara göre düşüktü. PVAD yokluğunda erişkin sıçan torasik aortunda elde edilen noradrenalin kasılmalarının boyu genç sıçan aortuna kıyasla anlamlı derecede yüksekti. Ancak bu arterlerde PVAD sağlam bırakıldığında, noradrenalin kasılma boyu ve duyarlılığı genç ve erişkin grupta benzerdi, bu da PVAD’ın erişkin sıçanlarda kasılma-karşıtı işlevinin devam ettiğini gösterdi. Genç sıçan torasik aortunda noradrenalin kasılmaları, nitrik oksit (NO) sentaz inhibitörü L-NAME varlığında güçlenerek arttı ve bu artış oranı PVAD varlığında daha düşüktü. Ancak, L-NAME'in erişkin grupta noradrenalin -aracılı kasılmalardaki güçlendirici etkisi PVAD varlığında değişmedi. Asetilkolin-kaynaklı ve endotel-bağımlı gevşemeler erişkin grupta genç gruba kıyasla önemli ölçüde azaldı. PVAD’ın sağlam bırakılması genç sıçan aortunda endotele bağlı gevşemeleri etkilemezken, yaşlı sıçan aortunda azalmış asetilkolin gevşemeleri daha da azaldı. Sonuç olarak, PVAD'ın kasılma-karşıtı işlevinin erişkin sıçanlarda devam ettiği ve tonik inhibitör etkiyle damardaki kasılmayı sınırladığı belirlenmiştir. Ancak, elde edilen verilere göre erişkin sıçan aortunda endotele bağlı gevşemelerin azalması ile birlikte PVAD ile endotel arasındaki çapraz sinyal etkileşiminin de bozulduğu düşünülmektedir.